| Income Statement | 2025-09-30 | |||
|---|---|---|---|---|
| Revenues, net | 1,413,535 | |||
| Cost of revenues | 1,356,330 | |||
| Gross profit | 57,205 | |||
| Research and development | 27,180,640 | |||
| Selling, general and administrative | 39,938,231 | |||
| Loss from operations | -67,061,666 | |||
| Loss on equity method investment | -141,007 | |||
| Interest income | 89,738 | |||
| Interest expense | -283,128 | |||
| Loss from change in fair value of promissory notes | 6,074,586 | |||
| Warrant inducement expenses (note 10) | 33,521,874 | |||
| Gain from change in fair value of warrant liability | -43,015,831 | |||
| Loss before income taxes | -63,976,692 | |||
| Income tax (benefit) expense | -1,551,829 | |||
| Net loss | -62,424,863 | |||
| Earnings per share, basic | -1.79 | |||
| Earnings per share, diluted | -1.79 | |||
| Weighted average number of shares outstanding, basic | 34,796,120 | |||
| Weighted average number of shares outstanding, diluted | 34,796,120 | |||
Outlook Therapeutics, Inc. (OTLK)
Outlook Therapeutics, Inc. (OTLK)